Cite
MLA Citation
David Gandara et al.. “Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.” Journal for immunotherapy of cancer, vol. 9, no. 3, 2021, p. . http://access.bl.uk/ark:/81055/vdc_100127584672.0x000025